There are. We've had some good progress with Health Canada even as we've started our advocacy efforts around the strategy. Within the strategy, we were looking at streamlining some of the regulatory processes around advanced cell therapies. They were typically regulated much like drugs. We've seen other jurisdictions, such as Japan, that have completely looked at cell therapies as a different category.
In regard to one of the things Health Canada has recently done, when we were talking with industry and developing a strategy, we first approved several cell therapy products here in Canada, but they haven't been commercialized here and the clinical trials haven't happened here. It's because we haven't had clarity around what the requirements are to move from a phase one to a phase two to a phase three trial. Health Canada has now released guidelines that were sitting on the shelf for quite some time. Those guidelines are there and they've now committed to work with us in industry to review those guidelines every six months. That has been one of the impediments to industry doing their trials here. We're working through that. There are more steps that we can take in terms of looking at this as a different class.